Press Releases

PTC is committed to serving the interests of all our stakeholders.
Pam & Kelsey
Living with PKU, United States

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Apr 26, 2016
PTC Therapeutics Appoints Dr. Tuyen Ong as Chief Medical Officer
SOUTH PLAINFIELD, N.J. , April 26, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that Tuyen Ong , M.D. has been promoted to Chief Medical Officer. Dr. Ong joined PTC in 2014 as the Senior Vice President, Head of Clinical Development and Translational Research .
Read More
Mar 14, 2016
PTC Therapeutics Announces Presentation of Results from Phase 3 ACT DMD Clinical Trial of Translarna™ (ataluren) in Patients with Duchenne Muscular Dystrophy at 5th International Congress of Myology
SOUTH PLAINFIELD, N.J. , March 14, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that data from the Phase 3, double-blind, placebo-controlled, 48-week ACT DMD trial of Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)
Read More